Undifferentiated gallbladder carcinoma
diseaseOn this page
Also known as anaplastic carcinoma of gallbladderanaplastic carcinoma of the gallbladderanaplastic gallbladder carcinomagall bladder undifferentiated carcinomagallbladder undifferentiated carcinomaundifferentiated carcinoma of gallbladderundifferentiated carcinoma of the gallbladderundifferentiated gallbladder cancer
Summary
Undifferentiated gallbladder carcinoma (MONDO:0006476) is a cancer and 1 clinical trial. Top therapeutic interventions include erlotinib hydrochloride and sorafenib. A subtype of gallbladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | undifferentiated gallbladder carcinoma |
| Mondo ID | MONDO:0006476 |
| EFO | EFO:1000604 |
| NCIT | C9167 |
| UMLS | C0279653 |
| MedGen | 76010 |
| GARD | 0024427 |
| Anatomy (UBERON) | UBERON:0002110 |
| Is cancer (heuristic) | yes |
Also known as: anaplastic carcinoma of gallbladder · anaplastic carcinoma of the gallbladder · anaplastic gallbladder carcinoma · gall bladder undifferentiated carcinoma · gallbladder undifferentiated carcinoma · undifferentiated carcinoma of gallbladder · undifferentiated carcinoma of the gallbladder · undifferentiated gallbladder cancer · undifferentiated gallbladder carcinoma
Data availability: 3 cell lines.
Disease family
This is a subtype of gallbladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gallbladder cancer › gallbladder carcinoma › undifferentiated gallbladder carcinoma
Related subtypes (4): gall bladder carcinoma in situ, gallbladder adenocarcinoma, gallbladder small cell neuroendocrine carcinoma, gallbladder squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01093222 | PHASE2 | COMPLETED | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ERLOTINIB HYDROCHLORIDE | 4 | 1 |
| SORAFENIB | 4 | 1 |